A citation-based method for searching scientific literature

Arshad M Khanani, Sunil S Patel, Philip J Ferrone, Aaron Osborne, Jayashree Sahni, Susanna Grzeschik, Karen Basu, Jason S Ehrlich, Zdenka Haskova, Pravin U Dugel. JAMA Ophthalmol 2020
Times Cited: 42







List of co-cited articles
285 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.
Jayashree Sahni, Pravin U Dugel, Sunil S Patel, Mark E Chittum, Brian Berger, Marta Del Valle Rubido, Shamil Sadikhov, Piotr Szczesny, Dietmar Schwab, Everson Nogoceke,[...]. JAMA Ophthalmol 2020
21
85

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Pravin U Dugel, Adrian Koh, Yuichiro Ogura, Glenn J Jaffe, Ursula Schmidt-Erfurth, David M Brown, Andre V Gomes, James Warburton, Andreas Weichselberger, Frank G Holz. Ophthalmology 2020
255
40

Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.
Jayashree Sahni, Sunil S Patel, Pravin U Dugel, Arshad M Khanani, Chirag D Jhaveri, Charles C Wykoff, Vrinda S Hershberger, Meike Pauly-Evers, Shamil Sadikhov, Piotr Szczesny,[...]. Ophthalmology 2019
77
38

Ranibizumab for neovascular age-related macular degeneration.
Philip J Rosenfeld, David M Brown, Jeffrey S Heier, David S Boyer, Peter K Kaiser, Carol Y Chung, Robert Y Kim. N Engl J Med 2006
35

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Jeffrey S Heier, David M Brown, Victor Chong, Jean-Francois Korobelnik, Peter K Kaiser, Quan Dong Nguyen, Bernd Kirchhof, Allen Ho, Yuichiro Ogura, George D Yancopoulos,[...]. Ophthalmology 2012
30

Phase I Trial of Anti-Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration.
Usha Chakravarthy, Clare Bailey, David Brown, Peter Campochiaro, Mark Chittum, Karl Csaky, Adnan Tufail, Paul Yates, Patrick Cech, Mylene Giraudon,[...]. Ophthalmol Retina 2017
33
36

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.
Jörg T Regula, Peter Lundh von Leithner, Richard Foxton, Veluchamy A Barathi, Chui Ming Gemmy Cheung, Sai Bo Bo Tun, Yeo Sia Wey, Daiju Iwata, Miroslav Dostalek, Jörg Moelleken,[...]. EMBO Mol Med 2016
96
28

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
David M Brown, Peter K Kaiser, Mark Michels, Gisele Soubrane, Jeffrey S Heier, Robert Y Kim, Judy P Sy, Susan Schneider. N Engl J Med 2006
28

Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease.
Rehan M Hussain, Ashley E Neiweem, Viral Kansara, Alon Harris, Thomas A Ciulla. Expert Opin Investig Drugs 2019
37
29

Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
Daniel F Martin, Maureen G Maguire, Gui-shuang Ying, Juan E Grunwald, Stuart L Fine, Glenn J Jaffe. N Engl J Med 2011
23

The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial.
Peter A Campochiaro, Dennis M Marcus, Carl C Awh, Carl Regillo, Anthony P Adamis, Vladimir Bantseev, Yawen Chiang, Jason S Ehrlich, Signe Erickson, William D Hanley,[...]. Ophthalmology 2019
103
23


Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study.
Derek Kunimoto, Young Hee Yoon, Charles C Wykoff, Andrew Chang, Rahul N Khurana, Raj K Maturi, Hansjürgen Agostini, Eric Souied, David R Chow, Andrew J Lotery,[...]. Ophthalmology 2020
36
22

Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration.
Frank G Holz, Ramin Tadayoni, Stephen Beatty, Alan Berger, Matteo G Cereda, Rafael Cortez, Carel B Hoyng, Philip Hykin, Giovanni Staurenghi, Stephanie Heldner,[...]. Br J Ophthalmol 2015
328
16

Efficacy of simultaneous VEGF-A/ANG-2 neutralization in suppressing spontaneous choroidal neovascularization.
Richard H Foxton, Sabine Uhles, Sabine Grüner, Franco Revelant, Christoph Ullmer. EMBO Mol Med 2019
14
50

Therapeutic targeting of the angiopoietin-TIE pathway.
Pipsa Saharinen, Lauri Eklund, Kari Alitalo. Nat Rev Drug Discov 2017
190
16

Innovative therapies for neovascular age-related macular degeneration.
Hasenin Al-Khersan, Rehan M Hussain, Thomas A Ciulla, Pravin U Dugel. Expert Opin Pharmacother 2019
43
16

Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).
Soraya Rofagha, Robert B Bhisitkul, David S Boyer, SriniVas R Sadda, Kang Zhang. Ophthalmology 2013
639
14

Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.
Wan Ling Wong, Xinyi Su, Xiang Li, Chui Ming G Cheung, Ronald Klein, Ching-Yu Cheng, Tien Yin Wong. Lancet Glob Health 2014
14

Faricimab: expanding horizon beyond VEGF.
Ashish Sharma, Nilesh Kumar, Baruch D Kuppermann, Francesco Bandello, Anat Loewenstein. Eye (Lond) 2020
22
27

HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Pravin U Dugel, Rishi P Singh, Adrian Koh, Yuichiro Ogura, Georges Weissgerber, Kinfemichael Gedif, Glenn J Jaffe, Ramin Tadayoni, Ursula Schmidt-Erfurth, Frank G Holz. Ophthalmology 2021
69
14

EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.
Adrian Koh, Won Ki Lee, Lee-Jen Chen, Shih-Jen Chen, Yehia Hashad, Hakyoung Kim, Timothy Y Lai, Stefan Pilz, Paisan Ruamviboonsuk, Erika Tokaji,[...]. Retina 2012
398
14

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis.
P C Maisonpierre, C Suri, P F Jones, S Bartunkova, S J Wiegand, C Radziejewski, D Compton, J McClain, T H Aldrich, N Papadopoulos,[...]. Science 1997
11

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies.
Wolfgang Schaefer, Jörg T Regula, Monika Bähner, Jürgen Schanzer, Rebecca Croasdale, Harald Dürr, Christian Gassner, Guy Georges, Hubert Kettenberger, Sabine Imhof-Jung,[...]. Proc Natl Acad Sci U S A 2011
252
11

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.
Jörg T Regula, Peter Lundh von Leithner, Richard Foxton, Veluchamy A Barathi, Gemmy Cheung Chui Ming, Sai Bo Bo Tun, Yeo Sia Wey, Daiju Iwata, Miroslav Dostalek, Jörg Moelleken,[...]. EMBO Mol Med 2019
9
55

Angiopoietin-2 is critical for cytokine-induced vascular leakage.
Andrew V Benest, Karoline Kruse, Soniya Savant, Markus Thomas, Anna M Laib, Elias K Loos, Ulrike Fiedler, Hellmut G Augustin. PLoS One 2013
89
11

Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study.
Salomon Y Cohen, Gerard Mimoun, Hassiba Oubraham, Alain Zourdani, Christian Malbrel, Stephane Queré, Véronique Schneider. Retina 2013
134
11

Ten years of anti-vascular endothelial growth factor therapy.
Napoleone Ferrara, Anthony P Adamis. Nat Rev Drug Discov 2016
454
11

Angiopoietin 2 induces pericyte apoptosis via α3β1 integrin signaling in diabetic retinopathy.
Sung Wook Park, Jang-Hyuk Yun, Jin Hyoung Kim, Kyu-Won Kim, Chung-Hyun Cho, Jeong Hun Kim. Diabetes 2014
91
11

Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation.
Minah Kim, Breanna Allen, Emilia A Korhonen, Maximilian Nitschké, Hee Won Yang, Peter Baluk, Pipsa Saharinen, Kari Alitalo, Christopher Daly, Gavin Thurston,[...]. J Clin Invest 2016
108
11

Tie1 controls angiopoietin function in vascular remodeling and inflammation.
Emilia A Korhonen, Anita Lampinen, Hemant Giri, Andrey Anisimov, Minah Kim, Breanna Allen, Shentong Fang, Gabriela D'Amico, Tuomas J Sipilä, Marja Lohela,[...]. J Clin Invest 2016
113
11

Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature.
Jikui Shen, Maike Frye, Bonnie L Lee, Jessica L Reinardy, Joseph M McClung, Kun Ding, Masashi Kojima, Huiming Xia, Christopher Seidel, Raquel Lima e Silva,[...]. J Clin Invest 2014
129
11

Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFβ1 in diabetic eyes undergoing vitrectomy.
Sirpa Loukovaara, Alexandra Robciuc, Juha M Holopainen, Kaisa Lehti, Timo Pessi, Johanna Liinamaa, Kirsi-Tiina Kukkonen, Matti Jauhiainen, Katri Koli, Jorma Keski-Oja,[...]. Acta Ophthalmol 2013
65
11

VEGF-Trap: a VEGF blocker with potent antitumor effects.
Jocelyn Holash, Sam Davis, Nick Papadopoulos, Susan D Croll, Lillian Ho, Michelle Russell, Patricia Boland, Ray Leidich, Donna Hylton, Elena Burova,[...]. Proc Natl Acad Sci U S A 2002
11

Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials.
Maureen G Maguire, Daniel F Martin, Gui-Shuang Ying, Glenn J Jaffe, Ebenezer Daniel, Juan E Grunwald, Cynthia A Toth, Frederick L Ferris, Stuart L Fine. Ophthalmology 2016
368
11

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
Daniel F Martin, Maureen G Maguire, Stuart L Fine, Gui-shuang Ying, Glenn J Jaffe, Juan E Grunwald, Cynthia Toth, Maryann Redford, Frederick L Ferris. Ophthalmology 2012
11

Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration.
David Callanan, Derek Kunimoto, Raj K Maturi, Sunil S Patel, Giovanni Staurenghi, Sebastian Wolf, Janet K Cheetham, Thomas C Hohman, Kimmie Kim, Francisco J López,[...]. J Ocul Pharmacol Ther 2018
41
12

Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study.
Rufino Silva, András Berta, Michael Larsen, Wayne Macfadden, Chrystel Feller, Jordi Monés. Ophthalmology 2018
133
11

THE ANGIOPOIETIN/TIE PATHWAY IN RETINAL VASCULAR DISEASES: A Review.
Jeffrey S Heier, Rishi P Singh, Charles C Wykoff, Karl G Csaky, Timothy Y Y Lai, Anat Loewenstein, Patricio G Schlottmann, Liliana P Paris, Peter D Westenskow, Carlos Quezada-Ruiz. Retina 2021
10
50

Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts.
Pipsa Saharinen, Lauri Eklund, Juho Miettinen, Riikka Wirkkala, Andrey Anisimov, Mark Winderlich, Astrid Nottebaum, Dietmar Vestweber, Urban Deutsch, Gou Young Koh,[...]. Nat Cell Biol 2008
308
9

Real-world Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration in the United States.
Thomas A Ciulla, Forbes Huang, Keith Westby, David F Williams, Sandi Zaveri, Samir C Patel. Ophthalmol Retina 2018
34
11

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Brandon G Busbee, Allen C Ho, David M Brown, Jeffrey S Heier, Ivan J Suñer, Zhengrong Li, Roman G Rubio, Phillip Lai. Ophthalmology 2013
332
9

Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation.
Ulrike Fiedler, Yvonne Reiss, Marion Scharpfenecker, Verena Grunow, Stefanie Koidl, Gavin Thurston, Nicholas W Gale, Martin Witzenrath, Simone Rosseau, Norbert Suttorp,[...]. Nat Med 2006
664
9

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
Ursula Schmidt-Erfurth, Peter K Kaiser, Jean-François Korobelnik, David M Brown, Victor Chong, Quan Dong Nguyen, Allen C Ho, Yuichiro Ogura, Christian Simader, Glenn J Jaffe,[...]. Ophthalmology 2014
514
9

Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
Pravin U Dugel, Glenn J Jaffe, Peter Sallstig, James Warburton, Andreas Weichselberger, Mark Wieland, Lawrence Singerman. Ophthalmology 2017
113
9

A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy.
Sampathkumar Rangasamy, Ramprasad Srinivasan, Joann Maestas, Paul G McGuire, Arup Das. Invest Ophthalmol Vis Sci 2011
90
9

Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1).
Christopher Daly, Vivian Wong, Elena Burova, Yi Wei, Stephanie Zabski, Jennifer Griffiths, Ka-Man Lai, Hsin Chieh Lin, Ella Ioffe, George D Yancopoulos,[...]. Genes Dev 2004
214
9

Angiopoietin 2 induces astrocyte apoptosis via αvβ5-integrin signaling in diabetic retinopathy.
J-H Yun, S W Park, J H Kim, Y-J Park, C-H Cho, J H Kim. Cell Death Dis 2016
34
11

Interfering with VE-PTP stabilizes endothelial junctions in vivo via Tie-2 in the absence of VE-cadherin.
Maike Frye, Martina Dierkes, Verena Küppers, Matthias Vockel, Janina Tomm, Dagmar Zeuschner, Jan Rossaint, Alexander Zarbock, Gou Young Koh, Kevin Peters,[...]. J Exp Med 2015
105
9

Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system.
Hellmut G Augustin, Gou Young Koh, Gavin Thurston, Kari Alitalo. Nat Rev Mol Cell Biol 2009
924
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.